Results 11 to 20 of about 1,300 (156)

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ahmad Masri, Miriam Elman, Hongya Chen   +2 more
exaly   +3 more sources

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population

Journal of the American Heart Association
Background Patients with obstructive hypertrophic cardiomyopathy have increased symptomatic burden. Mavacamten was recently approved for treatment of obstructive hypertrophic cardiomyopathy based on 2 randomized controlled trials.
Richard Carrick, Victoria Blake, Lili Barouch   +2 more
exaly   +3 more sources

Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system [PDF]

Open Heart
Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor Mavacamten can significantly improve patients’ symptomatic ...
Tingting Wu, Jiahao Zhang, Jialing Qian, Qingqing Jiang   +3 more
doaj   +2 more sources

Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions

Drug Design, Development and Therapy, 2023
Tiffany Dong,* Ben Alencherry,* Susan Ospina, Milind Y Desai Section of Cardiovascular Imaging, Heart, Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA*These authors contributed equally to this workCorrespondence: Milind ...
Tiffany Dong, Ben Alencherry, Milind Desai   +2 more
exaly   +2 more sources

Predictors of Higher Mavacamten Maintenance Dose in Obstructive Hypertrophic Cardiomyopathy [PDF]

Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mavacamten has emerged as an effective therapy for obstructive hypertrophic cardiomyopathy (oHCM); however, interindividual variability in maintenance dosing remains a practical challenge in clinical practice.
Mustafa Suppah, MD, Humam Abo Abdullah, MD, Amro Badr, MD, Ramzi Ibrahim, MD, Juan Farina, MD, Chadi Ayoub, MBBS, PhD, Reza Arsanjani, MD, Jeffrey Geske, MD, Said Alsidawi, MD   +8 more
doaj   +2 more sources

Comprehensive Review: Mavacamten and Aficamten in Hypertrophic Cardiomyopathy

Biomedicines
Hypertrophic cardiomyopathy (HCM) is the most common monogenic heart disease, with an estimated prevalence of 1:600 in the general population, and is associated with significant morbidity.
Helin Savsin, Tomasz Tokarek
doaj   +3 more sources

Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report. [PDF]

Case Rep Cardiol
Background Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by hypertrophy of the left ventricle that can lead to significant symptoms, particularly with exercise. For patients with HCM who demonstrate obstructive physiology, the first‐in‐class targeted cardiac specific myosin inhibitor, mavacamten, has been found to reduce the ...
Murthy N, Diep B, Evans J, Abramov D, Tran D.   +4 more
europepmc   +2 more sources

Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis

The Egyptian Heart Journal, 2023
Background Hypertrophic cardiomyopathy (HCM) is a hereditary myocardial disorder, often due to sarcomere gene mutations, characterized by the left ventricular hypertrophy. Current treatments offer symptomatic relief but lack specificity.
Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Syed Taha Ahmed, Burhanuddin Sohail Rangwala, Syed Raza Abbas   +5 more
doaj   +1 more source

Safety and efficacy of mavacamten for treatment of hypertrophic cardiomyopathy: a systematic review and meta-analysis of randomized clinical trials

The Egyptian Heart Journal, 2023
Background Mavacamten, an allosteric myosin inhibitor, is considered to be a promising drug for the treatment of hypertrophic cardiomyopathy (HCM). This meta-analysis aimed to explore the safety and efficacy of mavacamten in HCM patients.
Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Danial Habibi   +2 more
doaj   +1 more source

Study design and rationale of EXPLORER-CN: a phase III, randomised, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of mavacamten in Chinese adults with symptomatic obstructive hypertrophic cardiomyopathy

BMJ Open, 2023
Introduction Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease commonly caused by pathogenic genetic variants encoding sarcomere proteins.
Qing Zhang, Fang Wang, Yaling Han, Jing Sun, Shuyang Zhang, Wei Jin, Zhuang Tian, Ping Yang, Geng Wang, Jingmin Zhou, Peiwen Hsu   +10 more
doaj   +1 more source